Status:
COMPLETED
Study to Compare the Blood Levels of Sildenafil Following Administration of an Experimental Tablet vs. the Conventional Oral Tablet in Healthy Subjects.
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Erectile Dysfunction
Eligibility:
MALE
18-55 years
Phase:
PHASE1
Brief Summary
This study to will compare the blood levels of sildenafil following administration of an experimental tablet vs. the conventional oral tablet.
Eligibility Criteria
Inclusion
- Healthy males between the ages of 18 and 55 years. Body Mass Index of 18 to 30 kg/m2, and a total body weight \>50 kg (110 lbs).
Exclusion
- Smoking in excess of the equivalent of 5 cigarettes per day. Treatment with an experimental drug within 30 days or sildenafil, vardenafil, tadalfil within 4 days before first study dose.
- Develop blood pressure lowering or experience dizziness, lightheadedness when going from the laying down position to standing position.
Key Trial Info
Start Date :
October 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2008
Estimated Enrollment :
18 Patients enrolled
Trial Details
Trial ID
NCT00795938
Start Date
October 1 2008
End Date
November 1 2008
Last Update
February 1 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
New Haven, Connecticut, United States, 06511